Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.

Mira ChoiFriederike BachmannKaiyin WuNils LachmannDanilo SchmidtSusanne BrakemeierMichael DuerrAndreas KahlKai-Uwe EckardtKlemens BuddePeter Nickel

Published in: BMC nephrology (2020)

Rescue therapy with conversion to belatacept is feasible in patients with worsening renal function, even many years after transplantation. The benefit in patients with MVI and severe GFR impairment remains to be investigated.

Keyphrases

risk factors
oxidative stress
cell therapy
early onset
atomic force microscopy
stem cells
mass spectrometry